Combination chemotherapy with docetaxel and cisplatin as first-line treatment in advanced gastric cancer: is it a new effective chemotherapy?.
- Author:
Dong Bok SHIN
1
Author Information
1. Division of Hematology and Oncology, Gachon Medical School Gil Medical Center, Korea.
- Publication Type:Editorial
- Keywords:
Advanced gastric cancer;
Docetaxel;
Cisplatin
- MeSH:
Agranulocytosis;
Cisplatin*;
Drug Therapy*;
Drug Therapy, Combination*;
Fluorouracil;
Humans;
Prognosis;
Research Personnel;
Stomach Neoplasms*
- From:Korean Journal of Medicine
2007;72(6):577-579
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Advanced gastric carcinoma is associated with a poor prognosis. Although a number of combination chemotherapy regimens , usually based on 5FU and cisplatin, have been tested in randomized studies, there is no globally accepted standard therapy. Docetaxel is active against advanced gastric carcinoma and some investigators report a response rate ranging from 18% to 24% with a single-agent docetaxel. Kim et al performed a phase II trial with docetaxel plus cisplatin(DC) in patients with untreated advanced gastric cancer, which resulted in a response rate(per protocol population) of 42.4% but a response rate for the intent-to-treatment analysis is only 33.3%. Granulocytopenia worse than grade 3 occurred only in 7.6% in spite of older patients being included. Non-hematologic toxicities were negligible. The lower rate of hematologic and non-hematologic toxicities over a number of other studies is considered as clinically irrelevant. I would like to remind Dr Kim coutiously that he has to adress these discrepancies.
